Services on Demand
Journal
Article
English (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Similars in
SciELO
Share
Permalink
Cirugía y cirujanos
On-line version ISSN 2444-054XPrint version ISSN 0009-7411
Abstract
RUTEAGA-NAVARRO, Tanya C.; REYES-ROMERO, Miguel A. and TORRES-SALAZAR, Quitzia L.. Effect of sitagliptin on down-regulation of KAT7 and SIRT1 gene expression in breast cancer cell line MCF7. Cir. cir. [online]. 2023, vol.91, n.3, pp.334-338. Epub Sep 04, 2023. ISSN 2444-054X. https://doi.org/10.24875/ciru.22000189.
Background.
To date, the main clinical interest in DPP4 is focused on its inhibition in diabetic patients to prolong the half-life of incretins. Epigenetic alterations resulting from DPP4 inhibition have been poorly explored.
Objective.
The objective of this study was to determine, whether sitagliptin, a DPP4 inhibitor, has effects on the expression of KAT7 and SIRT1 (genes encoding a histone acetyltransferase and a histone deacetylase, respectively) in MCF7 breast cancer cells, which play an essential role in modulating the epigenetic landscape of chromatin.
Material and methods.
MCF7 cells were incubated for 20 h with sitagliptin at concentrations of 0.5, 1.0 and 2.0 μM. Total RNA was isolated and the relative mRNA expression of KAT7 and SIRT1 was determined by RT-qPCR.
Results.
There was downregulation in the relative expression of both genes; for KAT7, downregulation reached up to 0.49 (p = 0.027) and for SIRT1, it reached up to 0.55 (p = 0.037).
Conclusions.
These results suggest that sitagliptin has effects on the histone epigenetic landscape. This topic deserves further study due to the current sample use of DPP4 inhibitors in diabetic patients.
Keywords : Acetylation; DPP4; KAT7; MCF7; SIRT1.
